Aagami, Inc., is an Illinois based life sciences consulting firm offering,
- Strategic Consulting
- Out/In Licensing support
- Partnership / Co- development support
- Funding and Investment Advisory
- Divestiture/ M&A
- IP Licensing and Sale
- Market Entry / Development Strategy
In brief, Aagami brings:
- Deep Experience of overcoming business and socio-cultural differences of various countries/regions. Our partners have lived and worked in regions such as Japan, Spain, Germany, India, Colombia, apart from the US
- Extensive ‘C’ level network nurtured for over 20 years
- Global Deal making skills, honed for decades
- Partners having combined experience of 250+ years
- Supplementing bandwidth to save time, effort & cost
108+ Bio Pharma clients globally have put their trust in Aagami (175+ assignments) since last 20 years.
Aagami Inc. Corporate Presentation JPM 2024Aagami, Inc.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
Strategic Consulting
Out/In Licensing support
Partnership / Co- development support
Funding and Investment Advisory
Divestiture/ M&A
IP Licensing and Sale
Market Entry / Development Strategy
In brief, Aagami brings:
Deep Experience of overcoming business and socio-cultural differences of various countries/regions. Our partners have lived and worked in regions such as Japan, Spain, Germany, India, Colombia, apart from the US
Extensive ‘C’ level network nurtured for over 21 years
Global Deal making skills, honed for decades
Partners having combined experience of 250+ years
Supplementing bandwidth to save time, effort & cost
110+ Bio Pharma clients globally have put their trust in Aagami (180+ assignments) since last 21+ years.
Aagami Corporate Presentation March 2024Aagami, Inc.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. Out/In Licensing support
3. Partnership / Co- development support
4. Funding and Investment Advisory
5. Divestiture/ M&A
6. IP Licensing and Sale
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions. Our partners have lived and worked in regions such as Japan, Spain, Germany, India, Colombia, apart from the US.
2. Extensive ‘C’ level network nurtured for over 21 years.
3. Global Deal making skills, honed for decades.
4. Partners having combined experience of 250+ years.
5. Supplementing bandwidth to save time, effort & cost.
110+ Bio Pharma clients globally have put their trust in Aagami (180+ assignments) since last 21 years.
Aagami Corporate Presentation April 2022Aagami, Inc.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. In / Out Licensing
3. Partnership / Co- development
4. Funding and Investment Advisory
5. Divestiture/ Mergers / Acquisition
6. IP Licensing and Sale
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions
2. Extensive ‘C’ level network nurtured for over 19 years
3. Global Deal making skills, honed for decades
4. Partners having combined experience of 250+ years
5. Supplementing your bandwidth to save time, effort & cost
100+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. In / Out Licensing
3. Partnership / Co- development
4. Divestiture/ Mergers / Acquisition
5. IP Licensing and Sale
6. Funding and Investment Advisory
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions
2. Extensive ‘C’ level network nurtured for over 18 years
3. Global Deal making skills, honed for decades
4. Partners having combined experience of 250+ years
5. Supplementing your bandwidth to save time, effort & cost
95+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.
Aagami Technology Licensing PresentationAagami, Inc.
Aagami, Inc., is a life sciences consulting firm offering,
· Technology Licensing
· Strategic Consulting
· Market Intelligence
For Global companies in
· Technology Licensing Office of Universities
· Medical Devices & Technology
· Pharma
· Biotech
· Consumer Healthcare
· CROs, CDMOs
In Brief, Aagami Brings:
· Deep Experience of overcoming business and socio-cultural differences of various countries
· Extensive ‘C’ level network nurtured for over 15 years
· Global Deal making skills, honed for decades
· Partners having combined experience of 250+ years
· Supplementing your bandwidth to save time, effort & cost
75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Aagami Inc. Corporate Presentation JPM 2024Aagami, Inc.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
Strategic Consulting
Out/In Licensing support
Partnership / Co- development support
Funding and Investment Advisory
Divestiture/ M&A
IP Licensing and Sale
Market Entry / Development Strategy
In brief, Aagami brings:
Deep Experience of overcoming business and socio-cultural differences of various countries/regions. Our partners have lived and worked in regions such as Japan, Spain, Germany, India, Colombia, apart from the US
Extensive ‘C’ level network nurtured for over 21 years
Global Deal making skills, honed for decades
Partners having combined experience of 250+ years
Supplementing bandwidth to save time, effort & cost
110+ Bio Pharma clients globally have put their trust in Aagami (180+ assignments) since last 21+ years.
Aagami Corporate Presentation March 2024Aagami, Inc.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. Out/In Licensing support
3. Partnership / Co- development support
4. Funding and Investment Advisory
5. Divestiture/ M&A
6. IP Licensing and Sale
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions. Our partners have lived and worked in regions such as Japan, Spain, Germany, India, Colombia, apart from the US.
2. Extensive ‘C’ level network nurtured for over 21 years.
3. Global Deal making skills, honed for decades.
4. Partners having combined experience of 250+ years.
5. Supplementing bandwidth to save time, effort & cost.
110+ Bio Pharma clients globally have put their trust in Aagami (180+ assignments) since last 21 years.
Aagami Corporate Presentation April 2022Aagami, Inc.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. In / Out Licensing
3. Partnership / Co- development
4. Funding and Investment Advisory
5. Divestiture/ Mergers / Acquisition
6. IP Licensing and Sale
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions
2. Extensive ‘C’ level network nurtured for over 19 years
3. Global Deal making skills, honed for decades
4. Partners having combined experience of 250+ years
5. Supplementing your bandwidth to save time, effort & cost
100+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.
Aagami, Inc., is an Illinois based life sciences consulting firm offering,
1. Strategic Consulting
2. In / Out Licensing
3. Partnership / Co- development
4. Divestiture/ Mergers / Acquisition
5. IP Licensing and Sale
6. Funding and Investment Advisory
7. Market Entry / Development Strategy
In brief, Aagami brings:
1. Deep Experience of overcoming business and socio-cultural differences of various countries/regions
2. Extensive ‘C’ level network nurtured for over 18 years
3. Global Deal making skills, honed for decades
4. Partners having combined experience of 250+ years
5. Supplementing your bandwidth to save time, effort & cost
95+ Bio Pharma clients globally have put their trust in Aagami (150+ assignments) since 2003.
Aagami Technology Licensing PresentationAagami, Inc.
Aagami, Inc., is a life sciences consulting firm offering,
· Technology Licensing
· Strategic Consulting
· Market Intelligence
For Global companies in
· Technology Licensing Office of Universities
· Medical Devices & Technology
· Pharma
· Biotech
· Consumer Healthcare
· CROs, CDMOs
In Brief, Aagami Brings:
· Deep Experience of overcoming business and socio-cultural differences of various countries
· Extensive ‘C’ level network nurtured for over 15 years
· Global Deal making skills, honed for decades
· Partners having combined experience of 250+ years
· Supplementing your bandwidth to save time, effort & cost
75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Practice Areas: New Product Planning, Business Development and Licensing, Commercial Strategy and Analytics, and Epidemiology and Forecasting.
Our boutique expertise is focused on elucidating patient benefits of bio-pharmaceutical products, medical devices, and businesses. With insightful strategies and solutions aimed at planning and growing our clients’ business, our mission is to continue being the “go-to” firm and preferred partner for our clients in their commercial planning and R&D initiatives.
Our chief operating principle is an unsurpassable commitment to quality and our philosophy has been to develop and sustain strong long-term relationships with clients based on an in-depth understanding of client needs, rigorous research, sound methodologies, and keeping ahead of industry developments.
On February 23, 2015, the MIT Enterprise Forum of Philadelphia hosted a forum on raising money for early-stage life science and healthcare companies. In a discussion hosted by moderator Steve Bowman of Busclarity, panelists Jim Stuber and Bernard Rudnick addressed the subject from the point of view of founder and funder, respectively, with input on IP issues from Baker Hostetler's Jeffrey Rosedale.
Overview of services and programs offered through California Manufacturing Technology Consulting including ExporTech, Made in California, California Manufacturers Advantage, Lean Manufacturing, and more. By Lorri Aiello - CMTC
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Exhibitor Booth Partnering: Doing it RightBIOpartnering
There is an art to meeting more potential partners!
Exhibitors at the BIO International Convention get more meetings by starting early, checking often, tailoring meeting requests, and following up on non-responses.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Aagami Market Intelligence PresentationAagami, Inc.
Aagami, Inc., is a life sciences consulting firm offering,
· Market Intelligence
· Strategic Consulting
· Technology Licensing
For Global companies in
· Pharma
· Biotech
· Consumer Healthcare
· Technology Licensing Office of Universities
· Medical Devices & Technology
· CROs, CDMOs
In Brief, Aagami Brings:
· Deep Experience of overcoming business and socio-cultural differences of various countries
· Supplementing your bandwidth to save time, effort & cost
· Global Deal experience, honed for decades
· Partners having combined experience of 250+ years
· Extensive ‘C’ level network nurtured for over 15 years
75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.
Strategies for Conducting New Product Scientific Assessment - Yavuz SILAY - D...Yavuz Silay
Strategies for Conducting New Product Scientific Assessment - Due Diligence - New Strategies for Successful Licensing Acquisitions , DIA , Session Panel, June 22 2008,
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Can-Fite BioPharma Ltd. (NYSE American: CANF) is an advanced clinical-stage drug development company with a platform technology that addresses multi-billion-dollar markets in the treatment of autoimmune inflammatory diseases including Rheumatoid Arthritis and Psoriasis, and liver diseases including advanced liver cancer and NASH. Can-Fite’s drugs have an excellent safety profile with experience in over 1,000 patients. Can-Fite’s intellectual property portfolio consists of 13 patent families issued and pending. Piclidenoson and Namodenoson have been out-licensed in select territories with approximately $18 million received to date.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Practice Areas: New Product Planning, Business Development and Licensing, Commercial Strategy and Analytics, and Epidemiology and Forecasting.
Our boutique expertise is focused on elucidating patient benefits of bio-pharmaceutical products, medical devices, and businesses. With insightful strategies and solutions aimed at planning and growing our clients’ business, our mission is to continue being the “go-to” firm and preferred partner for our clients in their commercial planning and R&D initiatives.
Our chief operating principle is an unsurpassable commitment to quality and our philosophy has been to develop and sustain strong long-term relationships with clients based on an in-depth understanding of client needs, rigorous research, sound methodologies, and keeping ahead of industry developments.
On February 23, 2015, the MIT Enterprise Forum of Philadelphia hosted a forum on raising money for early-stage life science and healthcare companies. In a discussion hosted by moderator Steve Bowman of Busclarity, panelists Jim Stuber and Bernard Rudnick addressed the subject from the point of view of founder and funder, respectively, with input on IP issues from Baker Hostetler's Jeffrey Rosedale.
Overview of services and programs offered through California Manufacturing Technology Consulting including ExporTech, Made in California, California Manufacturers Advantage, Lean Manufacturing, and more. By Lorri Aiello - CMTC
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Genetic Technologies is a diversified molecular diagnostics company. A global leader in genomics-based tests in health, wellness and serious disease through its geneType and EasyDNA brands. GENE offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that has been developed over the past decade and integrates clinical and genetic risk to deliver actionable outcomes to physicians and individuals. Leading the world in risk prediction in oncology, cardiovascular and metabolic diseases, Genetic Technologies continues to develop risk assessment products.
Exhibitor Booth Partnering: Doing it RightBIOpartnering
There is an art to meeting more potential partners!
Exhibitors at the BIO International Convention get more meetings by starting early, checking often, tailoring meeting requests, and following up on non-responses.
Genetic Technologies Limited is a diversified molecular diagnostics company developing tools for the prediction and assessment of chronic disease risk to help physicians proactively manage patient health. The Company’s lead products, ‘GeneType for Breast Cancer’ and ‘GeneType for Colorectal Cancer’, are clinically validated risk assessment tests that are first in their class. The Company signed a multi-year distribution agreement for its COVID-19 Risk Test and remains on track to launch its revolutionary Multi-Test, covering up to 70% of mortalities and morbidities, including major oncological, metabolic, and degenerative diseases. Genetic Technologies recent acquisition of EasyDNA has significantly accelerated the Company’s commercialization strategy, providing established revenue streams and direct-to-consumer marketing channels that include 70 websites in 40 countries. Listed on the ASX in 2000 and NASDAQ in 2005, Genetic Technologies has been a leader in the development and commercialization of genetic risk assessment technology for 20 years.
Similar to Aagami Corporate Presentation 2023 (20)
Aagami Market Intelligence PresentationAagami, Inc.
Aagami, Inc., is a life sciences consulting firm offering,
· Market Intelligence
· Strategic Consulting
· Technology Licensing
For Global companies in
· Pharma
· Biotech
· Consumer Healthcare
· Technology Licensing Office of Universities
· Medical Devices & Technology
· CROs, CDMOs
In Brief, Aagami Brings:
· Deep Experience of overcoming business and socio-cultural differences of various countries
· Supplementing your bandwidth to save time, effort & cost
· Global Deal experience, honed for decades
· Partners having combined experience of 250+ years
· Extensive ‘C’ level network nurtured for over 15 years
75+ Bio Pharma clients globally across 125+ assignments have put their trust in Aagami since 2003.
Presentation made by Aagami at Lifesciences Summit at CGI - 18 MayAagami, Inc.
The Consulate General India - Chicago organized a Life Science Summit on May 18, 2015 at Chicago
Mr. Dinesh Jain, Founder CEO, Aagami Inc. and Mr. Michael Rosen, Managing Director, Rosen Bioscience Strategies (also partner consultant at Aagami) attended the event as speakers and made a presentation on “Life Science Connections between the Midwest and India” as well as some of the life science M&A and FDI activity going on between the U.S. and India”
Consulate General of India - Chicago - Lifescience summit AgendaAagami, Inc.
“Life Science Summit” on May 18, 2015 between 11:30am (Registration + Networking + Lunch) to 3:30pm.
Also attached is the agenda for the event.
Venue - 455 North Cityfront Plaza Drive, 8, NBC Tower, Chicago, IL 60611
Mr. Dinesh Jain, Founder CEO, Aagami Inc. and
Mr. Michael Rosen, Managing Director, Rosen Bioscience Strategies
will be attending as speakers and will make a presentation on
“Life Science Connections between the Midwest and India” as well as some of the life science M&A and FDI activity going on between the U.S. and India”
Study of Market Potential and Prospective Partners in India for hand-held qPC...Aagami, Inc.
Client:
Innovation Center of a New Zealand University focused on Health Sciences
Client Need:
A mobile, lightweight molecular diagnostic technology and device was developed at the University. Its Innovation center wanted to study the market potential in India.
As per Aagami’s suggestion, client agreed to include regulatory overview and potential partners in the study.
Results:
The report helped the University in determining conclusively on India market initiative.
Pleased with the report, the University appointed Aagami to find a licensing partner in India
Since its inception in February 2003, Aagami has assisted over 4 dozen small and large North/South American, European, Japanese and Australian companies in their initiatives. We have brought success to over 63% of our assignments and failed only 4% of the times.
Amazing Facts and Figures - A compilation by AagamiAagami, Inc.
Summary of Contents
India – an Introduction
India LifeSciences Industry Snapshot
Major Centers of Lifesciences in India – Public & Private
Major International Deals with India by Global Companies
What Indian LifeSciences firms are Looking for
About Aagami and how it supports global companies in their India Initiatives
CRISPR-Cas9, a revolutionary gene-editing tool, holds immense potential to reshape medicine, agriculture, and our understanding of life. But like any powerful tool, it comes with ethical considerations.
Unveiling CRISPR: This naturally occurring bacterial defense system (crRNA & Cas9 protein) fights viruses. Scientists repurposed it for precise gene editing (correction, deletion, insertion) by targeting specific DNA sequences.
The Promise: CRISPR offers exciting possibilities:
Gene Therapy: Correcting genetic diseases like cystic fibrosis.
Agriculture: Engineering crops resistant to pests and harsh environments.
Research: Studying gene function to unlock new knowledge.
The Peril: Ethical concerns demand attention:
Off-target Effects: Unintended DNA edits can have unforeseen consequences.
Eugenics: Misusing CRISPR for designer babies raises social and ethical questions.
Equity: High costs could limit access to this potentially life-saving technology.
The Path Forward: Responsible development is crucial:
International Collaboration: Clear guidelines are needed for research and human trials.
Public Education: Open discussions ensure informed decisions about CRISPR.
Prioritize Safety and Ethics: Safety and ethical principles must be paramount.
CRISPR offers a powerful tool for a better future, but responsible development and addressing ethical concerns are essential. By prioritizing safety, fostering open dialogue, and ensuring equitable access, we can harness CRISPR's power for the benefit of all. (2998 characters)
Antibiotic Stewardship by Anushri Srivastava.pptxAnushriSrivastav
Stewardship is the act of taking good care of something.
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
WHO launched the Global Antimicrobial Resistance and Use Surveillance System (GLASS) in 2015 to fill knowledge gaps and inform strategies at all levels.
ACCORDING TO apic.org,
Antimicrobial stewardship is a coordinated program that promotes the appropriate use of antimicrobials (including antibiotics), improves patient outcomes, reduces microbial resistance, and decreases the spread of infections caused by multidrug-resistant organisms.
ACCORDING TO pewtrusts.org,
Antibiotic stewardship refers to efforts in doctors’ offices, hospitals, long term care facilities, and other health care settings to ensure that antibiotics are used only when necessary and appropriate
According to WHO,
Antimicrobial stewardship is a systematic approach to educate and support health care professionals to follow evidence-based guidelines for prescribing and administering antimicrobials
In 1996, John McGowan and Dale Gerding first applied the term antimicrobial stewardship, where they suggested a causal association between antimicrobial agent use and resistance. They also focused on the urgency of large-scale controlled trials of antimicrobial-use regulation employing sophisticated epidemiologic methods, molecular typing, and precise resistance mechanism analysis.
Antimicrobial Stewardship(AMS) refers to the optimal selection, dosing, and duration of antimicrobial treatment resulting in the best clinical outcome with minimal side effects to the patients and minimal impact on subsequent resistance.
According to the 2019 report, in the US, more than 2.8 million antibiotic-resistant infections occur each year, and more than 35000 people die. In addition to this, it also mentioned that 223,900 cases of Clostridoides difficile occurred in 2017, of which 12800 people died. The report did not include viruses or parasites
VISION
Being proactive
Supporting optimal animal and human health
Exploring ways to reduce overall use of antimicrobials
Using the drugs that prevent and treat disease by killing microscopic organisms in a responsible way
GOAL
to prevent the generation and spread of antimicrobial resistance (AMR). Doing so will preserve the effectiveness of these drugs in animals and humans for years to come.
being to preserve human and animal health and the effectiveness of antimicrobial medications.
to implement a multidisciplinary approach in assembling a stewardship team to include an infectious disease physician, a clinical pharmacist with infectious diseases training, infection preventionist, and a close collaboration with the staff in the clinical microbiology laboratory
to prevent antimicrobial overuse, misuse and abuse.
to minimize the developme
Navigating the Health Insurance Market_ Understanding Trends and Options.pdfEnterprise Wired
From navigating policy options to staying informed about industry trends, this comprehensive guide explores everything you need to know about the health insurance market.
Struggling with intense fears that disrupt your life? At Renew Life Hypnosis, we offer specialized hypnosis to overcome fear. Phobias are exaggerated fears, often stemming from past traumas or learned behaviors. Hypnotherapy addresses these deep-seated fears by accessing the subconscious mind, helping you change your reactions to phobic triggers. Our expert therapists guide you into a state of deep relaxation, allowing you to transform your responses and reduce anxiety. Experience increased confidence and freedom from phobias with our personalized approach. Ready to live a fear-free life? Visit us at Renew Life Hypnosis..
Navigating Challenges: Mental Health, Legislation, and the Prison System in B...Guillermo Rivera
This conference will delve into the intricate intersections between mental health, legal frameworks, and the prison system in Bolivia. It aims to provide a comprehensive overview of the current challenges faced by mental health professionals working within the legislative and correctional landscapes. Topics of discussion will include the prevalence and impact of mental health issues among the incarcerated population, the effectiveness of existing mental health policies and legislation, and potential reforms to enhance the mental health support system within prisons.
Global launch of the Healthy Ageing and Prevention Index 2nd wave – alongside...ILC- UK
The Healthy Ageing and Prevention Index is an online tool created by ILC that ranks countries on six metrics including, life span, health span, work span, income, environmental performance, and happiness. The Index helps us understand how well countries have adapted to longevity and inform decision makers on what must be done to maximise the economic benefits that comes with living well for longer.
Alongside the 77th World Health Assembly in Geneva on 28 May 2024, we launched the second version of our Index, allowing us to track progress and give new insights into what needs to be done to keep populations healthier for longer.
The speakers included:
Professor Orazio Schillaci, Minister of Health, Italy
Dr Hans Groth, Chairman of the Board, World Demographic & Ageing Forum
Professor Ilona Kickbusch, Founder and Chair, Global Health Centre, Geneva Graduate Institute and co-chair, World Health Summit Council
Dr Natasha Azzopardi Muscat, Director, Country Health Policies and Systems Division, World Health Organisation EURO
Dr Marta Lomazzi, Executive Manager, World Federation of Public Health Associations
Dr Shyam Bishen, Head, Centre for Health and Healthcare and Member of the Executive Committee, World Economic Forum
Dr Karin Tegmark Wisell, Director General, Public Health Agency of Sweden
CHAPTER 1 SEMESTER V PREVENTIVE-PEDIATRICS.pdfSachin Sharma
This content provides an overview of preventive pediatrics. It defines preventive pediatrics as preventing disease and promoting children's physical, mental, and social well-being to achieve positive health. It discusses antenatal, postnatal, and social preventive pediatrics. It also covers various child health programs like immunization, breastfeeding, ICDS, and the roles of organizations like WHO, UNICEF, and nurses in preventive pediatrics.
Welcome to Secret Tantric, London’s finest VIP Massage agency. Since we first opened our doors, we have provided the ultimate erotic massage experience to innumerable clients, each one searching for the very best sensual massage in London. We come by this reputation honestly with a dynamic team of the city’s most beautiful masseuses.
Contact Now 89011**83002 Dehradun ℂall Girls By Full Service ℂall Girl In De...
Aagami Corporate Presentation 2023
1. → Realizing Possibilities, Together ←
Strategic Consulting |Global Advisory | Market Intelligence
108+
Clients
175+
Assignments
2020 Calamos Court, Suite 200, Naperville, IL 60653 USA | P: +1-630-364-1837 | www.aagami.com
30+
Countries
20+
Years
October 2023
2. - A life sciences consulting firm offering,
For companies worldwide in
Aagami, Inc.
Strategic Consulting Global Advisory Market Intelligence
Pharma Biotech Medical Devices
Consumer
Healthcare
2
3. Support all stages of
licensing
(Product/IP/Tech)
from Pre-Clinical to
on the Market
Various types of
development
partnering
support
Support in Divestment,
M&A, IP, Techs,
Companies, etc.
To augment your
bandwidth in
regions you want
support in.
Licensing/
Commercialization
Partnership /
Co-development
M&A/
Divestiture
Market
Entry/Development
Strategy
Your Needs, we Serve
Advisory and BD
support for
Funding and
Venture Capital
needs
Funding /
Investment
3
We provide these services to help you in achieving the following goals
4. Deep Experience of overcoming business and socio-cultural
differences of various countries/regions
Extensive ‘C’ level
network nurtured for
20+ years
Global Deal making
experience of 250+ years
of all Partners combined
Supplementary services of
Market Intelligence and
Business/IP research
Enhancing your
bandwidth for saving
time, effort & cost
Aagami brings,
4
Our partners have lived and worked in US, Japan, Germany, India, Spain, Colombia among others
5. Samples of diverse successes
Co-Development Partnership for
Novel Protein Therapeutic Platform.
2 Deals Done
Raising Investments for development of
therapeutic vaccines. Listing on OTC
Markets using reverse merger, US$ 10mn
deal signed
Technology Licensing of Dermal
Delivery Platform. 4 Deals signed
with 3 companies for 18 geographies
CONFIDENTIAL
Finding customers for Peptides API.
Partnered with 8 Companies
CONFIDENTIAL
5
Equity Investment from Large Pharma.
AU $17M initial deal done (AU$2M
first tranche paid). Total deal value of
AU $50M+
(More Details in Case Studies). In most cases, Deal size is CONFIDENTIAL
Investments Secured for Portable
MRI System
CONFIDENTIAL
6. USA International
6
Completed 175+ assignments for 108+ clients since 20+ years
Sample list of Clients
Japan
India
Netherland
Australia
Ireland
NFL BioSciences
France
UK
Sweden
Germany
S. Korea
Portugal
China
Belgium
Israel
7. Client Testimonials
7
Virtues include Aagami’s
attentiveness, network, and
integrity. Excellent and will
recommend to all
Aagami is the bridge that
crosses many gaps. Importantly
it does so openly and honestly.
Pleased by Aagami’s
professional and gracious work.
Delighted to recommend to
others
Other Consultants we worked
with in the US and Canada do
not even stand in Aagami’s
shadow
Founder and CEO of a California based Biopharma
Founder and CEO of a publicly Listed Australian
Technology Development Company
CEO of a Specialty Chemicals company based in Canada CEO of Oregon, US based Biotech
8. Aagami ‘s Proven Partnering Process
8
All these steps require 60 to 80 hours of effort every month depending upon scope
Setup Prospect Finalize
§ Capture important details about
your assets/technologies
§ Work with you to Finalize ‘Elevator
Pitch (EP)/Teaser’ customized to
specific business culture
§ Identify relevant companies and
decision makers from our
relationships , and resources, built
and nurtured over 20+years
§ Based on mutually agreed Criteria.
Shortlist is used after your review
and approval
§ Broadcast Elevator Pitch/Teaser by
email to identified Relevant
Companies
§ Follow-up with phone calls and
emails
§ Coordinate CDAs with interested
Companies
§ Facilitate further discussions and
due diligence
§ Organize conference calls for
clarifications
§ Organize and manage meetings
for deal finalization
§ Advise on structuring the
deal (Very important)
§ Support in negotiations
(Most critical)
§ Complete Agreement
Up to 1 month 3 to 5 months 1 to 12+ months
9. 9
Engagement Model - Monthly Commitment Fee + Success Fee
• This ‘brings skin in the
game’ of both parties
• After 6 months you may
choose to continue based
on progress and experience
• Modified Lehman
Formula of reducing % (7
to 3) is also available
• We get our profits only
from Success Bonus
• A team consisting of
Partner, Consultant & BD
Specialist is deployed
• Work with focus on your
success to get our bonus
Dedicated
Teamwork
Small Monthly
‘Commitment’
Fee
Success bonus
~80 hours/month/geography A small % of deal value
for at least 6 months
We can also work on a simple hourly basis with no minimums.
10. Dinesh Jain
• Founder CEO, MBA
• Working since 1984
• Lived and worked in 4
countries, 3 continents.
Michael
Rosen
Dr. Shridhar
Andurkar, Ph D. Nancy Chew
Dr. Aman Ahuja,
M.D., F.P.M., F.R.C.A.
Godwyn Francis
• Scientific Advisor
• Chair and Prof. of
Pharmaceutical sciences
• Midwestern Univ., Chicago
College of Pharmacy
• Working since 1991
Aagami - Core Team
• Partner, MBA
• Since 1974, Managed 3
MNC Pharma, Agritech,
• US, Europe, Latin
America, Japan & Israel
• Regulatory Expert
• Working since 1979
• A serial entrepreneur,
veteran business
leader, biochemist and
Pharmacologist
• Medical, Clinical
• Pain Specialist and
Anaesthetist uses
multidisciplinary
approach
• Practicing since 1998
• Vice President
• 35+ BioPharma clients
• Ex-Accenture, Prudential
plc, TATA, pManifold
• Working since 2000
Dr. Carlos Velez,
Ph D. MBA
• Partner
• Working since 1998
• CMTx , Lacerta, Connexin,
Panion, Ventac , Penwest,
Frankel
10
Cumulative experience
250+ years
Affiliate Partners based
in Europe and Asia
USA
USA
India
USA
USA
USA
Australia
11. Our expertise and experience is in BD and deal making
and we are Agnostic to types of drug, device or therapy
11
vWe are a firm that’s drug or therapy agnostic, we
work on the business side and are well connected
to decision makers across Biologics, Pharma and
Medtech companies of all sizes.
vWe have served several Biologics, Pharma and
Medical devices clients and are well positioned
to find you partnership(s).
12. 12
Some transactions did not further happen due to change in strategy by client/other reasons beyond Aagami control/Ongoing discussions
Select Term Sheet level successes (Last ~6 years only)
Client # of Term
sheets & Year
Client Country
1 (2023)
Ongoing
WI, USA
CDMO 2 (2022) USA
Ingenio Inc.
1 (2022) China
2 (2022, 2021) CA, USA
3 (2021) TX, USA
1 (2021) Sweden
2 (2021) Japan
1 (signed 2021) France
Client # of Term
sheets & Year
Client Country
2 (2020) Japan
2 (2019) Israel
1 (2019) Israel
3 (2018) Canada
2 (2017) Holland
2 (2017) UK
4 (2016) UK
3 (2016) NZ
HoneyLab
13. 13
1. Licensing available for Japan: Market ready
Denosumab biosimilar to PROLIA® & XGEVA®.
2. Licensing /Co-development - Phase 1 ready
NCE Oral small molecule modulator of
mutant RyR2 for the treatment of CPVT-1/
Heart Arrhythmia. Global/ Regional rights
available.
3. Seeking Partnering/JV/Acquisition –Smart
Drug preventing Myelodysplastic Syndromes
(MDS) from advancing to full-scale
myelogenous Leukemia. Second Human Trial
Ongoing in AU.
For Licensing/Partnering/Co-development:
4. Seeking Licensing/Co-development: Japanese
client’s Phase 2 (USA) stage Tizanidine patch using
proprietary ILTS technology for management of
spasticity.
5. Seeking Licensing/Co-development: Midwest US
based Pharma’s First-in-Class Non-Opioid
Analgesic for both chronic and acute Pain Relief.
Few client opportunities we are currently representing (1 of 3)
14. 14
Few client opportunities we are currently representing (2 of 3)
1. California based Mountain View Pharma (MVP) and its PharmaPEG®
technology, product candidates, data, & IP package - for Next-generation
biologics and substantial returns. Available at a very reasonable price.
2. Asset Sale - NCE Oral small molecule modulator of mutant RyR2 for the
treatment of CPVT-1/ Heart Arrhythmia (Phase 1 ready)
3. Asset Sale - Smart Drug preventing Myelodysplastic Syndromes (MDS) from
advancing to full-scale myelogenous Leukemia. Second Human Trial Ongoing in
AU.
For Acquisition
15. 15
Few client opportunities we are currently representing (3 of 3)
Investment Opportunities
1. Seeking US$15 million: Nose to brain
delivery (intra-nasal and bypassing the
blood brain barrier) technology
development company targeting orphan
diseases such as Frontotemporal
Dementia. Alzheimer’s disease, Dementia
with Lewy Bodies and Parkinson's disease.
2. Seeking US$5 million: A single
(monovalent) vaccine for Targeting
Salmonella, ETEC / E. coli, Campylobacter,
Shigella. Fulfills an unmet need for
treating Bacterial Dysentery.
3. Invest in the future with Integrated
Autoimmune Company: Seeking $40
million for Go to market campaign for
first product and key milestone for in-
development assets.
4. $40 Million Series C Open: On the market, US
FDA approved novel portable MRI Guided
Treatment, Diagnosis and Screening, for Urology
applications. California based client.
5. Seeking US$5 million: Midwest US based
Pharma with Phase 2 stage First-in-Class Non-
Opioid Analgesic NCE for Pain Relief.
16. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Equity Investment & Merger on Milestone
• Investments/JV/M&A for further development of its
Biotechnologies and commercialization
16
Australia based company developing novel Biotechnologies application in nutraceuticals
• Aagami identified right investors/ partners, and took them to
20 + companies.
• With focused efforts 3 companies had post CDA level
scientific and technical discussions.
• Aagami kept facilitating and persevering, 1 large company
moved to term sheet level discussions.
• Aagami travelled with client CEO to meet Chairman of
Strategic company in March 2020 to finalise the deal
• Supported client through structuring of the deal and
negotiations. Continued to support after the term sheet and
till definitive agreement was completed in March 2021.
• Large Pharma, acquired 12.5% stake in WRS (March 2021)
with a provision to acquire over 50% on agreed milestone.
• Based on the progress, the agreement has been signed for
100% acquisition.
Name of client partner is
CONFIDENTIAL
17. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Investment for First-in-Class Non-Opioid Analgesic NCE
• Investments and/or partnering to further develop
their lead asset CMX-020.
17
Milwaukee based pharmaceutical company focused on novel treatment for pain relief
• Aagami identified right investors/ partners, and took
them to 50 + companies who are operating in Pain /CNS
• Aagami brough 15+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering. several
companies expressed interest to partner sooner or later.
• Finally Aagami found an investor who transferred the
first tranche in May 2023.
• This enabled client to move one step further in their
development timeline.
• Aagami continues to look for further partnerships and
investments for the client.
• Secured first Investment in April 2023
• Enabled client to move to next steps in their
development timeline.
• Further prospecting in Progress. Client is very happy
and satisfied.
N
H
O
N
O
Log P: 5.01
CLogP: 5.101
CHNO••
Exact Mass: 43.01
Mol. Wt.: 43.02
CNO•••
Exact Mass: 42.00
Mol. Wt.: 42.02
C26H44N2O2
Exact Mass: 416.34
Mol. Wt.: 416.64
CMX-020
18. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Partnerships for Development and Commercialisation of
Novel Class of Protein Drugs
• The client wanted collaborative partners to develop novel
drugs in Oncology and Ophthalmology using their new class
of proteins - Anticalins®.
German Biotech company making differentiated Novel drugs
• Aagami identified right partners, and took them to 7
interested companies
• With focused efforts three companies moved to term sheet
level discussions. Two companies remained for final
negotiations.
• Aagami maintained its spirits and perseverance knowing
Indian ways of working; even when client was ready to give
up as per Western ways.
• Finally co-development partnership happened in next few
months with one company in Oncology and with another
company for ophthalmic therapy.
• Identifying right companies, advice on deal structure,
perseverance & commitment were the key success factors.
• Client signed co-development deals with 2 companies
in Oct and Dec 2013 respectively
• Aagami proved highly influential in negotiations for
finalization of the deals due to deep experience in
business culture nuances of India.
• The deals helped Pieris in their NASDAQ (PIRS) listing
in 2014, and also enabled higher valuation.
18
19. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Investment for development of therapeutic vaccines
• Investments and partnering to further develop its
technologies and pipeline.
19
Louisiana, US based biotechnology company specializing in innovative cancer treatments
• Aagami scanned the global market, identified right investors/
partners, and took them to 50 + companies.
• With focused efforts 10+ companies had post CDA level
scientific and clinical discussions.
• Aagami kept facilitating and persevering, 3 companies
moved to term sheet level discussions.
• Finally Aagami found a right partner to facilitate reverse
merger with a OTC Markets listed company.
• This enabled access to large sums of funds to develop
clinical stage programs.
• Listing on OTC Markets by a reverse merger
• Financial resources to enable development of existing
pipeline and technologies
20. Case
Study
Client
Client Need
Solution Approach
Results
**Data has been sanitized and meant for Illustrative purposes only
Out-licensing of Transdermal Drug Delivery Technology
• To Out-License TPM® Technology and Co-Develop in clinic
products using proprietary Delivery technology and market
such products in India and larger region.
20
TPM® Technology and Products Company from Australia
• Aagami scanned numerous companies and got 10 relevant
companies interested.
• Discussion with 8 companies progressed.
• Took client to India 3 times for term sheet level meetings
and deal signing.
• Facilitated entire evaluation and deal structuring process
• Aagami made sure testing and other protocols were
honoured before deal was made.
• During the process Aagami ensured clear understanding
despite socio cultural differences in styles of working.
• 4 Deals done with 3 global companies
– The first deal was for diclofenac topical gel formulation with
TPM. The Indian partner not only launched their own
product but also out licensed to a major western pharma.
Expanded to 16 more geographies worldwide in 2016.
– The second alliance was for use in Skin Whitening and
under eye cream.
– Third deal – The prospect using TPM increased bio
availability as well as stability of a specific antibiotic. Then
sold off that division for $1.6B
21. Offerings in Market Intelligence/Business Research
Competitive
Landscape
Assessments
Analysis of
Portfolio
Opportunities
identification
Price Discovery
Research
Due Diligence
IP and Regulatory
Research
Financial
Modeling, NPV
valuations
New Market Entry
strategy
Market
development
strategy
21
On need basis at one time cost
22. Aagami, Inc.
2020 Calamos Court, Suite 200
Naperville, IL 60653, USA
+1-630-364-1837
www.aagami.com
22
CONTACT US
June 05-08
Meet us at:
Godwyn Francis
Vice-President
godwyn@aagami.com
M: +1-630-909-3341
Dinesh Jain
Founder CEO
dinesh@aagami.com
M: +1 630-853-3520